The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA]
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein]
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA]
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein]
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein]
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein]
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein]
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]
lysophosphatidic acid results in increased activity of RHOC protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein]
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium]
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein]
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein
14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] 14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7)
CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]; 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased transport of 8-epi-prostaglandin F2alpha]; 14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased abundance of angiotensin I (1-7)]; 14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein]; 14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased transport of Nitrogen Oxides]
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid]
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA]
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA]
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]
glyceryl 2-arachidonate analog results in increased expression of CXCL8 protein; glyceryl 2-arachidonate results in increased expression of CXCL8 protein [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein
glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate
[palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] glyceryl 2-arachidonate affects the localization of PPARA protein
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA]
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate]
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate
MGLL protein results in increased degradation of 2-oleoylglycerol Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol]
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]
CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]
[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid
eleostearic acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein]; eleostearic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] eleostearic acid results in decreased activity of CAT protein
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in decreased phosphorylation of IRS1 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K1 protein
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K3 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K3 protein
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA mRNA; [trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased expression of PPARG protein]; [cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased expression of PPARG protein
cis-9, trans-11-conjugated linoleic acid results in increased expression of SLC2A4 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA]
cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]; cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] cis-9, trans-11-conjugated linoleic acid affects the expression of TNF mRNA
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL8 mRNA] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA]
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]]
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to oxaliplatin]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]]
[caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [Masoprocol results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Sulindac results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Vorinostat results in increased expression of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]
NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein] alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA; alpha-Linolenic Acid results in increased expression of CYP2A6 protein
CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] alpha-Linolenic Acid results in decreased activity of CYP2C19 protein
alpha-Linolenic Acid results in decreased activity of CYP2C9 protein CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]
[[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [[alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA; [alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA; fulvestrant inhibits the reaction [[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA]
alpha-Linolenic Acid results in increased expression of HMOX1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]]
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in increased expression of IL1B protein alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]
NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]
alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] alpha-Linolenic Acid binds to NR1H4 protein
alpha-Linolenic Acid binds to and results in increased activity of PPARA protein PPARA protein affects the abundance of alpha-Linolenic Acid alpha-Linolenic Acid results in increased expression of PPARA mRNA alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Calcitriol promotes the reaction [alpha-Linolenic Acid results in increased expression of PPARA mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of alpha-Linolenic Acid]
alpha-Linolenic Acid binds to and results in increased activity of PPARB protein alpha-Linolenic Acid results in increased expression of PPARD mRNA; Calcitriol results in increased expression of [alpha-Linolenic Acid results in increased expression of PPARD mRNA]
alpha-Linolenic Acid results in increased expression of PPARG mRNA alpha-Linolenic Acid results in increased activity of PPARG protein alpha-Linolenic Acid binds to and results in increased activity of PPARG protein
alpha-Linolenic Acid results in increased expression of PTGS2 mRNA alpha-Linolenic Acid results in increased expression of PTGS2 protein alpha-Linolenic Acid results in decreased expression of PTGS2 mRNA
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]]
alpha-Linolenic Acid results in increased expression of VDR mRNA [Calcitriol co-treated with alpha-Linolenic Acid] results in increased expression of VDR mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]
anandamide results in decreased phosphorylation of CREB1 protein anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]
[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide] FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] FAAH results in increased degradation of anandamide anandamide affects the expression of FAAH protein
anandamide analog binds to FABP1 protein FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein]
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in increased degradation of ABCA1 protein
Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]
Arachidonic Acid results in increased phosphorylation of AKT1 protein aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein]
ALOX15 protein affects the metabolism of Arachidonic Acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid ALOX15 protein results in increased metabolism of Arachidonic Acid [IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in decreased expression of APOA1 mRNA
APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein]
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]
Arachidonic Acid results in decreased expression of BCL2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]
Arachidonic Acid results in decreased expression of BCL2L1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]
Arachidonic Acid results in increased cleavage of BID protein FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]
Arachidonic Acid results in increased activity of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]
Arachidonic Acid results in decreased activity of CES1 protein [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein] [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
Arachidonic Acid results in increased phosphorylation of CREB1 protein Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein]
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA] CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein] Arachidonic Acid results in increased secretion of CXCL8 protein
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]
CYP1A1 protein affects the metabolism of Arachidonic Acid Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein]
Arachidonic Acid results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased metabolism of Arachidonic Acid CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]
CYP2C9 protein results in increased metabolism of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP2C9 protein CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Arachidonic Acid]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid] CYP2E1 protein affects the hydroxylation of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP2E1 protein
CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]
FAAH protein results in increased chemical synthesis of Arachidonic Acid Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid]
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein] Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein
[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA] Arachidonic Acid results in decreased phosphorylation of FOS protein
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]
[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein]
Arachidonic Acid results in increased expression of HMOX1 mRNA NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] Arachidonic Acid metabolite results in increased expression of HMOX1 mRNA; Arachidonic Acid metabolite results in increased expression of HMOX1 protein HMOX1 protein results in decreased susceptibility to Arachidonic Acid
[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA
Arachidonic Acid results in increased secretion of INS protein Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]
Arachidonic Acid results in increased expression of ITGA2B protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]]
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]
Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein] Arachidonic Acid results in increased expression of JUN mRNA
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA] Arachidonic Acid results in increased expression of JUNB mRNA
Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein
Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]
LIPC gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid
LIPG gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid
FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]
Arachidonic Acid results in increased phosphorylation of MAPK1 protein MAPK1 protein affects the abundance of Arachidonic Acid [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]
MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein] MAPK3 protein affects the abundance of Arachidonic Acid
MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]
Arachidonic Acid results in increased phosphorylation of MAPT protein Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein]
Arachidonic Acid results in increased secretion of MMP13 protein Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein]
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein]
Arachidonic Acid results in increased expression of MMP9 mRNA Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein]
Arachidonic Acid results in increased secretion of MPO protein 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein]
Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] Arachidonic Acid metabolite results in increased expression of NFE2L2 protein
Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]]
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA] PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein
Arachidonic Acid results in increased expression of PLIN2 mRNA Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein
Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Arachidonic Acid results in decreased activity of PON1 protein
Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein Arachidonic Acid binds to and results in increased activity of PPARA protein
Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein Arachidonic Acid results in increased expression of PPARG protein Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA]
Arachidonic Acid results in increased activity of PTGS1 protein PTGS1 results in increased susceptibility to Arachidonic Acid PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]
[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 protein PTGS2 results in increased susceptibility to Arachidonic Acid 12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein
Arachidonic Acid results in increased expression of SELP protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]
Arachidonic Acid results in decreased activity of SOD1 protein Arachidonic Acid results in increased activity of SOD1 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]
[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein] Arachidonic Acid results in increased activity of SOD2 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]
Arachidonic Acid results in increased expression of STAR protein Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]
Arachidonic Acid results in decreased expression of THRSP mRNA Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA]
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid] TNF protein results in increased abundance of Arachidonic Acid Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]
TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid [TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in increased activity of TRPA1 protein Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein]
[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein] Arachidonic Acid results in increased expression of VEGFA mRNA
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein [Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein
[arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]
[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyl-2-chloroethylamide results in increased activity of MPO protein Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]
arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA
arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]
arachidonyl-2-chloroethylamide results in increased activity of RHOA protein AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]
Castor Oil results in increased expression of PAFAH1B1 protein isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein]
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate LIPG gene mutant form results in increased abundance of cholesteryl linolenate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate LIPG gene mutant form results in increased abundance of cholesteryl oleate
Linoleic Acids, Conjugated results in increased expression of ADGRE1 mRNA; Linoleic Acids, Conjugated results in increased expression of ADGRE1 protein
[picolinic acid co-treated with Linoleic Acids, Conjugated] results in increased expression of ADIPOQ protein Linoleic Acids, Conjugated results in decreased expression of ADIPOQ protein
Linoleic Acids, Conjugated results in decreased expression of ADIPOR2 mRNA rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of ADIPOR2 mRNA]
Linoleic Acids, Conjugated results in decreased expression of CD36 mRNA rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of CD36 mRNA]
Linoleic Acids, Conjugated results in increased expression of CXCL8 mRNA resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of CXCL8 mRNA]
Linoleic Acids, Conjugated results in decreased phosphorylation of and results in decreased activity of ESR1 protein; Okadaic Acid inhibits the reaction [Linoleic Acids, Conjugated results in decreased phosphorylation of ESR1 protein]
Linoleic Acids, Conjugated results in increased activity of GCLC protein [Linoleic Acids, Conjugated results in increased activity of GCLC protein] which results in decreased susceptibility to tert-Butylhydroperoxide Linoleic Acids, Conjugated results in increased expression of GCLC mRNA
Linoleic Acids, Conjugated results in increased activity of GSK3B protein Linoleic Acids, Conjugated results in decreased phosphorylation of GSK3B protein
Linoleic Acids, Conjugated results in increased expression of IL1B mRNA resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of IL1B mRNA]
Linoleic Acids, Conjugated results in increased expression of IL6 mRNA; Linoleic Acids, Conjugated results in increased expression of IL6 protein Linoleic Acids, Conjugated results in decreased expression of IL6 protein [Chromium co-treated with Linoleic Acids, Conjugated] results in decreased expression of IL6 protein resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of IL6 mRNA]
[Linoleic Acids, Conjugated co-treated with Chromium] results in decreased expression of INS1 protein Linoleic Acids, Conjugated results in decreased expression of INS1 protein
Linoleic Acids, Conjugated results in decreased expression of INS protein Linoleic Acids, Conjugated results in increased susceptibility to INS protein
[Linoleic Acids, Conjugated co-treated with Chromium] results in decreased expression of LEP protein Linoleic Acids, Conjugated results in decreased expression of LEP protein Linoleic Acids, Conjugated results in increased expression of LEP protein
rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of LPL mRNA] Linoleic Acids, Conjugated results in increased activity of LPL protein
Linoleic Acids, Conjugated inhibits the reaction [Acrolein results in decreased activity of OGDH protein] Linoleic Acids, Conjugated results in increased activity of OGDH protein
Linoleic Acids, Conjugated results in decreased activity of PPARG protein Linoleic Acids, Conjugated results in increased expression of PPARG mRNA Linoleic Acids, Conjugated results in increased expression of PPARG mRNA; Linoleic Acids, Conjugated results in increased expression of PPARG protein Linoleic Acids, Conjugated results in increased phosphorylation of and results in increased activity of PPARG protein; resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in decreased activity of PPARG protein]; resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased phosphorylation of and results in increased activity of PPARG protein] Linoleic Acids, Conjugated results in decreased expression of PPARG protein
Linoleic Acids, Conjugated results in increased expression of PTGS2 mRNA; Linoleic Acids, Conjugated results in increased expression of PTGS2 protein [Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost; resveratrol inhibits the reaction [[Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost]; resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of PTGS2 mRNA]
Corn Oil results in decreased expression of CAT protein [bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in decreased expression of CAT protein
Corn Oil affects the expression of CPT1A mRNA [bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT1A mRNA Corn Oil results in increased expression of CPT1A mRNA
Corn Oil affects the expression of CROT mRNA [bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CROT mRNA
[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein; Dactinomycin inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]; Orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
Corn Oil results in decreased expression of IL4 mRNA Corn Oil results in increased expression of IL4 mRNA Corn Oil results in increased secretion of IL4 protein
[Corn Oil co-treated with Iron, Dietary] results in decreased activity of SOD1 protein; [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]; Iron, Dietary promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]
erucic acid promotes the reaction [Doxorubicin results in increased expression of NOS2 protein] erucic acid results in increased expression of NOS2 protein
erucic acid results in increased expression of NOS3 protein erucic acid promotes the reaction [Doxorubicin results in increased expression of NOS3 protein]
[Flurbiprofen results in decreased activity of AKR1C3 protein] which results in increased chemical synthesis of farnesoic acid; [tolfenamic acid results in decreased activity of AKR1C3 protein] which results in increased chemical synthesis of farnesoic acid
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of CLDN5 protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of CLDN5 protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of CLDN5 protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of CLDN5 protein
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of OCLN protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of OCLN protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of OCLN protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of OCLN protein
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of TJP1 protein
cyclohexene inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Oxygen inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; propanethiol inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
ALOX5 protein results in increased secretion of Leukotriene B4 ALOX5 protein results in increased chemical synthesis of Leukotriene B4 [benoxaprofen results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [RS 43179 results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Tamoxifen results in increased expression of ALOX5 protein] which results in increased abundance of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]; ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; kaempferol inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3-O-glucuronide inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Quercetin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] [[A 78773 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[CMI 392 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[zileuton co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene B4; [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [tepoxalin results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [troglitazone results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [CXCL8 protein results in increased abundance of Leukotriene B4]; tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]]
ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; L 655238 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]
Leukotriene B4 results in decreased expression of BAX mRNA; Leukotriene B4 results in decreased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]
CCL12 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CCL12 protein results in increased abundance of Leukotriene B4]
zileuton inhibits the reaction [CCL2 protein results in increased abundance of Leukotriene B4] Leukotriene B4 results in increased expression of CCL2 protein
[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4; Dexamethasone inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]
Leukotriene B4 inhibits the reaction [zileuton inhibits the reaction [Histamine results in increased expression of CXCL8 protein]] Leukotriene B4 results in increased expression of CXCL8 mRNA; Leukotriene B4 results in increased expression of CXCL8 protein
CXCL1 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CXCL1 protein results in increased abundance of Leukotriene B4]
[2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone results in increased activity of HSD11B2 protein]; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein] Leukotriene B4 results in decreased expression of HSD11B2 mRNA Leukotriene B4 results in decreased activity of HSD11B2 protein
[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]
IL13 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [IL13 protein results in increased abundance of Leukotriene B4]
IL4 protein inhibits the reaction [Calcimycin results in increased metabolism of Leukotriene B4]; IL4 protein inhibits the reaction [Zymosan affects the metabolism of Leukotriene B4]
Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]] LTB4 increases expression of ITGAM protein on neutrophils and monocytes
Leukotriene B4 results in increased expression of ITGB2 protein Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]
1-(4-(benzothiazol-2-yloxy)benzyl)piperidine-4-carboxylic acid inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; cyclohexene inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Oxygen inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; propanethiol inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]
[SC 41930 binds to and results in decreased activity of LTB4R protein] which results in decreased abundance of Leukotriene B4; Leukotriene B4 binds to and affects the activity of LTB4R1 protein Leukotriene B4 binds to and results in increased activity of LTB4R protein; LY 255283 analog inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 255283 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 293111 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein] LTB4R1 protein affects the susceptibility to Leukotriene B4 Leukotriene B4 analog binds to LTB4R1 protein
Leukotriene B4 results in increased expression of MCL1 mRNA; Leukotriene B4 results in increased expression of MCL1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]
Leukotriene B4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites]
PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4]; PLA2G4A protein promotes the reaction [Zymosan analog results in increased metabolism of Leukotriene B4]
ABCC1 protein affects the transport of Leukotriene C4 [Nimustine results in increased expression of ABCC1 protein] which results in increased transport of Leukotriene C4; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Bilirubin inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; estradiol-17 beta-glucuronide inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Glutathione Disulfide promotes the reaction [Leukotriene C4 analog binds to ABCC1 protein]; Glutathione promotes the reaction [Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; kaempferol inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; myricetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Quercetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4] ABCC1 protein mutant form results in decreased transport of Leukotriene C4
ABCC2 protein modified form results in increased transport of Leukotriene C4 verlukast inhibits the reaction [ABCC2 protein results in increased transport of Leukotriene C4] ABCC2 protein affects the transport of Leukotriene C4
[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene C4 [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene C4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]]
[2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4; [MK-886 results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4
CLEC7A protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; CLEC7A protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
[Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CGP 57698 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein; MEN91507 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein] CYSLTR1 protein binds to and affects the susceptibility to Leukotriene C4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene C4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein
Leukotriene C4 results in increased expression of EDN1 mRNA; Leukotriene C4 results in increased expression of EDN1 protein zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein]
[Beclomethasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4; [Fluticasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4
Leukotriene C4 results in increased expression of IL13 mRNA [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein
Leukotriene C4 binds to and results in decreased activity of MGST1 protein; Leukotriene C4 inhibits the reaction [Glutathione binds to and results in increased activity of MGST1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]
Leukotriene C4 results in increased expression of MUC5AC mRNA; Leukotriene C4 results in increased expression of MUC5AC protein [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein
Leukotriene C4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites]
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4] PLA2G5 protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]; Colchicine inhibits the reaction [RALBP1 protein affects the transport of Leukotriene C4]
SYK protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; SYK protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
ALOX5 protein results in increased abundance of Leukotriene D4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene D4
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]
[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CGP 57698 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]; iralukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; LY 171883 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; MEN91507 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; montelukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pobilukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pranlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; pranlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; verlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CYSLTR1 protein binds to and affects the susceptibility to Leukotriene D4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased chemical synthesis of inositol 1-phosphate; [Leukotriene D4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium]; Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB1 protein]; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB2 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]
Leukotriene D4 results in increased activity of GPR17 protein montelukast inhibits the reaction [Leukotriene D4 results in increased activity of GPR17 protein]
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]
IL13 protein results in increased abundance of Leukotriene D4 [IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]
[IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC mRNA]; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC protein] Leukotriene D4 results in increased expression of MUC5AC mRNA; Leukotriene D4 results in increased expression of MUC5AC protein
6,7-dimethoxy-3-phenylquinoxaline inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; bisindolylmaleimide I inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; pobilukast inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]
Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of SRC protein; pobilukast inhibits the reaction [Leukotriene D4 results in increased activity of SRC protein]
Leukotriene D4 promotes the reaction [CSF2 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [ICAM1 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [IL5 protein results in increased expression of TGFB1 protein]
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]
ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene E4
Leukotriene E4 binds to CYSLTR1 protein [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein; montelukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein
1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein] Linoleic Acid analog results in decreased expression of ABCA1 mRNA Linoleic Acid results in increased expression of ABCA1 mRNA Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] Linoleic Acid results in increased phosphorylation of ABCA1 protein
AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]
Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]
Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein]
Linoleic Acid results in increased expression of CAT protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased activity of CAT protein]
CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein] CNR1 protein affects the susceptibility to Linoleic Acid
NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein] Linoleic Acid results in increased expression of CYP2A6 mRNA; Linoleic Acid results in increased expression of CYP2A6 protein
[Linoleic Acid co-treated with Testosterone] results in increased expression of FADS2 mRNA FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein] Linoleic Acid results in increased expression of FADS2 mRNA; Linoleic Acid results in increased expression of FADS2 protein
NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA] Linoleic Acid metabolite results in increased expression of HMOX1 mRNA; Linoleic Acid metabolite results in increased expression of HMOX1 protein
Linoleic Acid results in increased expression of IL1B protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL1B mRNA]
Linoleic Acid affects the expression of IL6 protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL6 mRNA] Linoleic Acid results in increased expression of IL6 mRNA Linoleic Acid results in increased secretion of IL6 protein
FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]; TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]
Linoleic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Linoleic Acid results in decreased expression of and results in decreased activity of MMP9 protein [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein] Linoleic Acid results in decreased expression of MMP9 mRNA
Linoleic Acid metabolite results in increased expression of NFE2L2 protein; Linoleic Acid results in increased expression of NFE2L2 mRNA; Linoleic Acid results in increased expression of NFE2L2 protein NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein]
PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]
Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Linoleic Acid results in decreased activity of PON1 protein
[Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased oxidation of Linoleic Acid; Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]; Linoleic Acid binds to and results in increased activity of PPARA protein; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein] Linoleic Acid results in increased expression of PPARA mRNA PPARA protein affects the abundance of Linoleic Acid Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Linoleic Acid]; Linoleic Acid binds to and results in increased activity of PPARA protein Linoleic Acid results in increased expression of PPARA mRNA; Linoleic Acid results in increased expression of PPARA protein Linoleic Acid results in increased activity of PPARA protein Linoleic Acid binds to PPARA protein
Linoleic Acid binds to and results in increased activity of PPARB protein Linoleic Acid results in decreased expression of PPARD mRNA Linoleic Acid binds to PPARB protein Linoleic Acid results in increased expression of PPARD mRNA Linoleic Acid results in increased activity of PPARD protein
Linoleic Acid binds to PPARG protein Linoleic Acid binds to and results in increased activity of PPARG protein Linoleic Acid results in increased expression of PPARG mRNA resveratrol inhibits the reaction [Linoleic Acid results in increased expression of PPARG protein] Linoleic Acid results in increased activity of PPARG protein Linoleic Acid results in decreased expression of PPARG mRNA; Linoleic Acid results in decreased expression of PPARG protein
Linoleic Acid results in increased expression of PTGS2 mRNA Linoleic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
Linoleic Acid results in increased expression of SCD mRNA; Linoleic Acid results in increased expression of SCD protein [Linoleic Acid co-treated with Testosterone] results in increased expression of SCD mRNA
Linoleic Acid results in decreased susceptibility to TNF protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TNF mRNA]
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]
lipoxin A4 analog inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; lipoxin A4 analog inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; lipoxin A4 inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased secretion of CXCL8 protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein] lipoxin A4 analog results in decreased expression of CXCL8 protein
[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA] lipoxin A4 results in increased activity of FPR2
lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]
lipoxin A4 analog results in decreased expression of IL1B protein 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] lipoxin A4 analog results in decreased secretion of IL1B protein lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]
lipoxin A4 analog results in increased secretion of IL4 protein lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]
lipoxin A4 results in increased phosphorylation of MAPK9 protein Gentamicins inhibits the reaction [lipoxin A4 results in increased phosphorylation of MAPK9 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]
lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein] Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TNF protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]] N-oleoyldopamine results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ABCA1 mRNA; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Oleic Acid results in increased expression of ABCA1 mRNA Oleic Acid results in increased phosphorylation of ABCA1 protein Oleic Acid results in increased degradation of ABCA1 protein Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAA2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA Oleic Acid results in increased expression of ACAA2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA; cyhalothrin promotes the reaction [Oleic Acid results in increased expression of ACACA protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACB mRNA
[Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of ACAD9 mRNA]
[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA] [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADM mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADM mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADS mRNA Oleic Acid results in increased expression of ACADS mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADVL mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADVL mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT2 mRNA
[[Vehicle Emissions results in increased abundance of Particulate Matter] which co-treated with Oleic Acid] results in decreased expression of ACLY mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACLY mRNA Oleic Acid results in decreased expression of ACLY mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT12 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA Oleic Acid results in increased expression of ACOT12 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT7 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT7 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Fenofibrate co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [tesaglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA]
[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA Oleic Acid results in decreased expression of ACOX2 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ACSL1 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACSL4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA
Oleic Acid results in decreased expression of ADIPOQ mRNA sophocarpine inhibits the reaction [Oleic Acid results in decreased expression of ADIPOQ mRNA]
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AGPAT2 mRNA Oleic Acid results in increased expression of AGPAT2 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AHR mRNA
Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein] [Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of AKT1 protein Oleic Acid results in decreased phosphorylation of AKT1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]
[ALB protein binds to Oleic Acid] promotes the reaction [ALB protein results in increased reduction of Dithionitrobenzoic Acid]; [ALB protein binds to Oleic Acid] promotes the reaction [Pyruvaldehyde results in increased oxidation of ALB protein]; [ALB protein modified form binds to Oleic Acid] which results in decreased reduction of Dithionitrobenzoic Acid; [Oleic Acid co-treated with muraglitazar] results in increased expression of ALB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ALB mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ALB mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein]; Quercetin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ANGPTL4 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ANXA2 mRNA
Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Oleic Acid results in increased expression of APOA5 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of APOB protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of APOB protein]; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein]; Oleic Acid results in increased expression of and results in increased secretion of APOB protein Oleic Acid results in decreased expression of APOB mRNA [Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA]; Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein]
[Oleic Acid co-treated with muraglitazar] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with rosiglitazone] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of APOC3 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of APOE mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOE mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ARG1 mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of ATF6 mRNA]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of B4GALT5 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA Oleic Acid results in increased cleavage of CASP3 protein Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased cleavage of CASP3 protein]
IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein] 3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; Quercetin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased activity of CAT protein] Oleic Acid results in increased activity of CAT protein [Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased activity of CAT protein; [Oleic Acid co-treated with Palmitic Acid] results in increased activity of CAT protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased activity of CAT protein]; gossypin inhibits the reaction [Oleic Acid results in increased activity of CAT protein]
GW 4064 inhibits the reaction [Oleic Acid results in increased expression of CD36 protein] [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA] Oleic Acid results in increased expression of CD36 mRNA [Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CIDEC mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of COL1A1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of COL1A1 mRNA]
Oleic Acid results in increased expression of CPT1A mRNA Oleic Acid results in decreased expression of CPT1A mRNA [Starch co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Sucrose co-treated with Oleic Acid] results in increased expression of CPT1A mRNA [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA] [Farnesol analog co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT1A mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; isosilybin promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of CPT1A mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of CPT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA]
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of CRP protein
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CXCL8 mRNA; Quercetin inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of CXCL8 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL2 mRNA
[Oleic Acid co-treated with anastrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with letrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein
[Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 mRNA]; [Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 protein] Oleic Acid results in increased expression of CYP1A1 mRNA; Oleic Acid results in increased expression of CYP1A1 protein
Oleic Acid results in decreased expression of CYP1A2 mRNA Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP1A2 mRNA]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP24A1 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP26A1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of CYP2B6 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP2B6 mRNA]
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of CYP2E1 mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA] [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2E1 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in increased expression of CYP2E1 mRNA]
Oleic Acid results in decreased expression of CYP7A1 mRNA [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA [Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 mRNA]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of DECR1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of DGAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of DGAT2 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of DHDDS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of DHDDS mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DST mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1H1 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1I1 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of ECH1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of ECH1 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EGFR mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein] Oleic Acid results in increased phosphorylation of EGFR protein
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EIF2AK3 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ELOVL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Fenofibrate] affects the expression of ELOVL6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ELOVL6 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ELOVL6 mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA
Oleic Acid binds to FABP1 protein Oleic acid binds to Fabp1 protein [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FABP1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FABP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of FABP1 mRNA; Dibutyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Diethylhexyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Oleic Acid inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] Bezafibrate inhibits the reaction [Oleic Acid binds to FABP1 protein]
[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of FABP4 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of FABP4 mRNA Oleic Acid analog affects the localization of FABP4 protein Oleic Acid results in increased expression of FABP4 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FAS mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein] Oleic Acid results in increased expression of FAS mRNA
[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of FASN mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FASN mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein; [Oleic Acid co-treated with Fenofibrate] affects the expression of FASN mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein] [Sucrose co-treated with Oleic Acid] results in increased expression of FASN mRNA [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of FASN mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FASN mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FDFT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FDFT1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of FDPS mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FGF21 mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of FNTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FNTA mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FOXA1 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of FOXO1 protein; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein]
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein]
[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein; Acetylcysteine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; Chloroquine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; exenatide inhibits the reaction [[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein]; Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein; wortmannin inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein] Oleic Acid affects the localization of GLP1R protein
[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein; acadesine inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]
Oleic Acid results in increased expression of GPAT3 mRNA [GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT3 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of GPAT3 mRNA
[Farnesol analog co-treated with Oleic Acid] results in increased expression of GPAT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT4 mRNA
[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein]
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]
Oleic Acid results in decreased phosphorylation of GSK3B protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADH mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADH mRNA
Oleic Acid results in increased expression of HADHA mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADHA mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHA mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHA mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHB mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHB mRNA]; Oleic Acid promotes the reaction [GW 7647 results in increased expression of HADHB mRNA]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HIF1A protein
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HILPDA protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HMGCR mRNA [[Palmitic Acid co-treated with Oleic Acid] co-treated with IFNA2 protein alternative form] results in decreased expression of HMGCR protein
[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]
sophocarpine inhibits the reaction [Oleic Acid results in increased expression of HNF4A protein] [Palmitic Acid co-treated with Oleic Acid] affects the expression of HNF4A mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HSDL2 mRNA
Oleic Acid results in increased expression of HSPA5 mRNA [Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of HSPA5 mRNA]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein] [Palmitic Acid co-treated with Oleic Acid] affects the expression of HSPA5 mRNA
[perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL18 mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL18 protein
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of IL1A mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL1B protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA]
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; [Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein; Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein] Oleic Acid results in decreased expression of IL6 mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of IL6 protein] Oleic Acid results in increased expression of IL6 mRNA; Oleic Acid results in increased expression of IL6 protein
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] Oleic Acid results in increased secretion of INS1 protein Oleic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]
[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein] [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with alitretinoin] results in increased uptake of Oleic Acid
Oleic Acid results in decreased phosphorylation of INSR protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]
IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein]; Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of JAK1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of JAK1 protein
[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of LAMB1 mRNA
Oleic Acid results in decreased expression of LEP mRNA Oleic Acid results in increased expression of LEP mRNA sophocarpine inhibits the reaction [Oleic Acid results in increased expression of LEP mRNA]
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid Oleic Acid results in decreased expression of LIPC mRNA [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of LIPC mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LIPC mRNA; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of LIPC mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of LPIN1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA Oleic Acid results in decreased expression of LPIN3 mRNA
[Palmitic Acid co-treated with Oleic Acid] affects the expression of MAP1LC3B mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased lipidation of MAP1LC3B protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MCAT mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MCAT mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA]
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein]
[GW 4064 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MTTP mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of MTTP mRNA]
[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein] [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA] Oleic Acid results in increased expression of NFE2L2 mRNA; Oleic Acid results in increased expression of NFE2L2 protein
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein]
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of NR0B2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA Oleic Acid results in increased expression of NR0B2 mRNA Oleic Acid results in decreased expression of NR0B2 mRNA
[Oleic Acid co-treated with Fenofibrate] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with rosiglitazone] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with tesaglitazar] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with troglitazone] affects the expression of NR1H3 mRNA [Oleic Acid co-treated with Palmitic Acid] results in increased expression of NR1H3 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of NR1H4 mRNA; [Oleic Acid co-treated with Fenofibrate] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of NR1H4 mRNA Oleic Acid results in decreased expression of NR1H4 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Troglitazone] affects the expression of NR1I3 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein; resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA]; resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein]
Oleic Acid results in increased cleavage of PARP1 protein [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]
[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of PCK1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PCK1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PCK1 mRNA
Oleic Acid results in increased expression of PDK4 mRNA [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PDSS1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PDSS1 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PEBP1 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of PECR mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PECR mRNA Oleic Acid results in decreased expression of PECR mRNA
PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PKLR mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN2 mRNA; Oleic Acid promotes the reaction [LG 100268 results in increased expression of PLIN2 protein]; Oleic Acid promotes the reaction [pirinixic acid results in increased expression of PLIN2 protein] Rimonabant inhibits the reaction [Oleic Acid results in increased expression of PLIN2 protein] Oleic Acid results in increased expression of PLIN2 mRNA; Oleic Acid results in increased expression of PLIN2 protein [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 protein; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Dichlorodiphenyl Dichloroethylene promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]
Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA]
[GW 4064 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PNPLA3 mRNA
[Calcium co-treated with Oleic Acid] results in increased stability of PON1 protein; Calcium promotes the reaction [Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [Hydrogen Peroxide results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] Oleic Acid results in decreased activity of PON1 protein
Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Oleic Acid]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid inhibits the reaction [Troglitazone results in decreased expression of PPARA mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC13A1 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of ABCD3 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP2C65 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP4F16 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC27A4 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC6A3 mRNA] Oleic Acid binds to PPARA protein Oleic Acid results in increased expression of PPARA mRNA; Oleic Acid results in increased expression of PPARA protein [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARA mRNA; [tetrabromobisphenol A co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein] Oleic Acid results in decreased expression of PPAR mRNA; Oleic Acid results in decreased expression of PPARA mRNA; Oleic Acid results in decreased expression of PPARA protein [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PPARA mRNA; [Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of PPARA mRNA]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased activity of and results in increased localization of PPARA protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PPARA protein]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid results in increased activity of and results in increased localization of PPARA protein; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein] Oleic Acid results in increased activity of PPARA protein
Oleic Acid binds to and results in increased activity of PPARB protein Oleic Acid results in decreased expression of PPARD mRNA [Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of PPARD mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA]; Oleic Acid binds to and results in increased activity of PPARB protein; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA] Oleic Acid results in increased expression of PPARD mRNA [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PPARD mRNA; Oleic Acid binds to and results in increased activity of PPARB protein
Oleic Acid results in increased expression of PPARG mRNA Oleic Acid binds to PPARG protein [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of PPARG mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA] [cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARG mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARG mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein]; Oleic Acid binds to and results in increased activity of PPARG protein Oleic Acid results in increased expression of PPARG mRNA; Oleic Acid results in increased expression of PPARG protein
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]
Oleic Acid results in increased expression of PTGS2 mRNA dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of RABGGTB mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of RHOB mRNA
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ROCK2 protein
[Starch co-treated with Oleic Acid] results in increased expression of SCD1 mRNA; [Sucrose co-treated with Oleic Acid] results in increased expression of SCD1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of SCD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA] Oleic Acid results in decreased expression of SCD mRNA
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SCD5 mRNA Oleic Acid results in decreased expression of SCD5 mRNA
[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]
Oleic Acid results in increased expression of SIRT1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased activity of SIRT1 protein]; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein] [Ethanol co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SIRT1 protein
Oleic Acid results in increased expression of SLC25A20 protein [Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC25A20 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC27A1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SLC27A2 mRNA
Oleic Acid results in increased expression of SLC2A2 mRNA [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of SLC2A2 mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of SLC2A2 mRNA]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SNAP23 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SNHG14 mRNA; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SOCS2 mRNA
Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in decreased secretion of SOD1 protein]; gastrodin inhibits the reaction [Oleic Acid results in decreased expression of SOD1 mRNA]
Oleic Acid results in increased expression of SOD2 mRNA [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA
Oleic Acid results in increased expression of SQSTM1 protein [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein]; necrostatin-1 inhibits the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]
Oleic Acid results in increased expression of SREBF1 mRNA Oleic Acid results in increased expression of SREBF1 mRNA; Oleic Acid results in increased expression of SREBF1 protein [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA [Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; sophocarpine inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA] [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Dibutyl Phthalate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of SREBF1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 protein] Oleic Acid results in decreased expression of SREBF1 mRNA; Oleic Acid results in decreased expression of SREBF1 protein
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]
[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein]
Oleic Acid results in increased expression of TGFB1 protein Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TGFB1 protein]
Bezafibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TIMP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of TIMP1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TIMP1 mRNA]
Oleic Acid results in decreased susceptibility to TNF protein Oleic Acid results in increased expression of TNF mRNA; Oleic Acid results in increased expression of TNF protein [Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein] [Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ENO3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ERLIN1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PLD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PRKAA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RAB18 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHEB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SLC2A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOCS1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TNFAIP2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TUBB2A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CXCL8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FLOT1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of LDLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP3K8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS3 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF protein]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA
Oleic Acid results in increased expression of UCP2 mRNA [Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in decreased expression of UCP2 protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein] Oleic Acid results in decreased expression of UCP2 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of UGCG mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VAMP4 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VCAN mRNA
Oleic Acid promotes the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of VNN1 mRNA]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased splicing of XBP1 mRNA]
palmitoleic acid results in increased degradation of ABCA1 protein palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] palmitoleic acid results in increased phosphorylation of ABCA1 protein
palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
palmitoleic acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; palmitoleic acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] palmitoleic acid results in decreased activity of PON1 protein
Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]
Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of ACACA mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of ACACA mRNA]
Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]
Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of FASN mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of FASN mRNA]
Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased abundance of Triglycerides]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of ACACA mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of FASN mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 protein]]
Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 protein]]
browse the term
